Pelthos Therapeutics (PTHS) Receivables (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly Receivables of $8.9 million for Q4 2025, up 10.89% quarter-over-quarter from $8.0 million in Q3 2025.

Pelthos Therapeutics (PTHS) Receivables (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' Receivables history runs 1 years deep, the most recent figure standing at $8.9 million for Q4 2025.

In Q4 2025, Receivables changed N/A year-over-year to $8.9 million; the TTM figure through Dec 2025 stood at $8.9 million (changed N/A YoY), while the FY2025 annual figure was $8.9 million, up 21825.74% from the prior year.
Receivables for Q4 2025 stood at $8.9 million, up from $8.0 million in the prior quarter.
The five-year high for Receivables was $8.9 million in Q4 2025, with the low at $8.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Pelthos Therapeutics	91.09 Mn	66.53 Mn	21.23 Mn	14.48 Mn

Download Data